Investigational drug · Phase 3
AXS-05
Also called: dextromethorphan-bupropion
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Smoking Cessation.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
16
Any phase or sponsor naming "AXS-05"
First trial start
2021
Jun 17, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AXS-05", any sponsor or status.
Conditions studied
As listed on its trial records.
- Agitation in Patients With Dementia of the Alzheimer's Type
- Alzheimer Disease
- Smoking Cessation
- Agitation
- Agitation, Psychomotor
Approved drugs for the same conditions: Alzheimer's disease · Smoking cessation · Neurology · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "AXS-05" as an intervention, largest first.
- Open-Label Safety Study of AXS-05 in Subjects With DepressionPivotal-lookingCompleted
Axsome Therapeutics, Inc.Industry
NCT04039022 · 876 participants · Start Jul 8, 2019 · Primary completion Oct 23, 2020
Drug: AXS-05 (dextromethorphan and bupropion) oral tablets · For: Major Depressive Disorder; Treatment Resistant Depression; Depression
Sites: Phoenix, Arizona; Little Rock, Arkansas; Bellflower, California · 51 sites in all
- Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)Pivotal-lookingRecruiting
Axsome Therapeutics, Inc.Industry
NCT07766655 · 705 participants (planned) · Start Aug 27, 2026 · Primary completion Dec 2027
Drug: AXS-05 (dextromethorphan-bupropion); Bupropion and 1 more · For: Smoking Cessation
Sites: Phoenix, Arizona; Little Rock, Arkansas; Lemon Grove, California · 28 sites in all
- A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease AgitationPivotal-lookingCompleted
Axsome Therapeutics, Inc.Industry
NCT04947553 · 456 participants · Start Jun 17, 2021 · Primary completion Dec 3, 2024
Drug: AXS-05 (dextromethorphan-bupropion); Placebo · For: Agitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation, Psychomotor
Sites: Peoria, Arizona; Tempe, Arizona; Long Beach, California · 47 sites in all
- A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease AgitationPivotal-lookingCompleted
Axsome Therapeutics, Inc.Industry
NCT05557409 · 408 participants · Start Sep 6, 2022 · Primary completion Nov 21, 2024
Drug: AXS-05; Placebo · For: Agitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation
Sites: Peoria, Arizona; Tempe, Arizona; Tucson, Arizona · 55 sites in all
- Addressing Dementia Via Agitation-Centered EvaluationPivotal-lookingCompleted
Axsome Therapeutics, Inc.Industry
NCT03226522 · 366 participants · Start Jul 13, 2017 · Primary completion Apr 17, 2020
Drug: AXS-05; Bupropion and 1 more · For: Agitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation,Psychomotor
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 78 sites in all
- A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive SymptomsPivotal-lookingRecruiting
Axsome Therapeutics, Inc.Industry
NCT06223880 · 350 participants (planned) · Start Dec 27, 2023 · Primary completion Mar 2026
Drug: AXS-05; Bupropion · For: Major Depressive Disorder
Sites: Bellflower, California; Lafayette, California; Oceanside, California · 40 sites in all
- A Trial of AXS-05 in Patients With Major Depressive DisorderPivotal-lookingCompleted
Axsome Therapeutics, Inc.Industry
NCT04019704 · 327 participants · Start Jun 20, 2019 · Primary completion Nov 26, 2019
Drug: AXS-05; Placebo · For: Depression; Major Depressive Disorder
Sites: Phoenix, Arizona; Little Rock, Arkansas; Bellflower, California · 43 sites in all
- A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive DisorderPivotal-lookingCompleted
Axsome Therapeutics, Inc.Industry
NCT02741791 · 312 participants · Start Mar 2016 · Primary completion Mar 20, 2020
Drug: AXS-05; Bupropion · For: Treatment Resistant Major Depressive Disorder
Sites: Phoenix, Arizona; Little Rock, Arkansas; Anaheim, California · 74 sites in all
- An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent PatientsPivotal-lookingStatus unknown
Axsome Therapeutics, Inc.Industry
NCT04971291 · 312 participants (planned) · Start Apr 14, 2021 · Primary completion Jul 2021
Drug: AXS-05; Bupropion SR · For: Major Depressive Disorder; Treatment Resistant Depression
Sites: New York, New York
Axsome Therapeutics, Inc.Industry
NCT04634669 · 181 participants · Start Sep 23, 2020 · Primary completion Feb 18, 2022
Drug: AXS-05 (dextromethorphan-bupropion) · For: Treatment Resistant Depression; Major Depressive Disorder
Sites: Little Rock, Arkansas; Redlands, California; Sherman Oaks, California · 20 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Healthcare utilization and costs associated with dextromethorphan-bupropion versus selected other branded treatments for major depressive disorder: a US real-world study.
Citrome L, Zhao Y, Zeni C, et al. · J Med Econ 2026
- Concerns About the Evidence Supporting Dextromethorphan-Bupropion in Depression.
Kennedy KP · Am J Psychiatry 2026
- Concerns About the Evidence Supporting Dextromethorphan-Bupropion in Depression: Response to Kennedy.
Tabuteau H · Am J Psychiatry 2026
- Dextromethorphan-Bupropion-Esketamine Triadic Pharmacology: Molecular Targets, Enzymatic Interactions, and Risk-Benefit Assessment of a Three-Agent Combination for Treatment-Resistant Depression.
Fagiolini A, Cuomo A, Corrivetti G, et al. · Int J Mol Sci 2026
- Reply to: Dextromethorphan-Bupropion (Auvelity)-A Drug to Avoid Prescribing, Even if it Were Free.
Brown EE, Semla T, Reuben DB · J Am Geriatr Soc 2026
- Dextromethorphan as a Potentially Safer Treatment for Agitation Associated With Dementia Due to Alzheimer's Disease.
Kverno K · J Psychosoc Nurs Ment Health Serv 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.